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Abstract Lapatinib and capecitabine (L-CAP) is effec-
tive in HER-2 positive patients with metastatic breast
cancer (MBC). However, moderate to severe diarrhea and
rash (C grade 2) are problematic dose limiting toxicities.
Since risk may vary over the course of therapy, we
developed repeated measures models to predict the risk
of C grade 2 diarrhea and rash prior to each cycle of
L-CAP. Data from 197 patients who received the L-CAP as
part of a clinical trial were reviewed (Cameron, Breast
Cancer Res Treat 112:533–543, 2008). Generalized esti-
mating equations were used to develop the risk models
using a backward elimination process. Risk scoring algo-
rithms were then derived from the final model coefficients.
Finally, a receiver operating characteristic curve (ROC)
analysis was undertaken to measure the predictive accuracy
of the scoring algorithms. Patient age, presence of skin
metastases at baseline, treatment being initiated in the
spring, earlier cycles, and grade I diarrhea in the prior cycle
were identified as being significant predictors for C grade
2 diarrhea. The ROC analysis indicated good predictive
accuracy for the diarrhea algorithm with an area under the
curve of 0.78 (95 %CI: 0.72–0.82). Prior to each cycle of
therapy, patients with risk scores [ 125 units would be
considered at high risk for developing C grade 2 diarrhea.
A similar prediction index was also derived in the case
of C grade 2 rash. Our models provide patient-specific risk
information that could be helpful in assessing the risks and
benefits of L-CAP in the MBC patients.
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Introduction
Lapatinib is an orally administered tyrosine kinase inhibi-
tor of the epidermal growth factor receptor (EGFR)
(ErbB1) and human epidermal growth factor receptor-2
(HER-2) [1]. Early trials reported clinical activity in HER-
2 positive breast cancer, even in patients with prior expo-
sure to trastuzumab suggesting the lack of cross-resistance
[2]. In the pivotal trial that led to approval by regulatory
agencies, good performance status patients with advanced
stage HER-2 positive breast cancer who had received prior
treatment with trastuzumab, anthracyclines, and taxanes
were randomized to receive lapatinib 1,250 mg daily with
capecitabine (L-CAP) or to capecitabine alone. At the
interim analysis, the median time to progression was
8.4 months in the experimental group compared to
4.4 months in the control (HR = 0.49; p = 0.0069) [3].
Since the threshold for statistical significance in the pri-
mary endpoint was met, the Data Safety and Monitoring
Committee recommended terminating enrollment and
allowing women in the control arm to be offered lapatinib
[3, 4].
Despite the almost two fold increase in progression free
survival and substantial clinical activity in patients with
brain metastases [4, 5], the L-CAP combination can be
associated with significant dose limiting toxicities (DLT),
G. Dranitsaris (&)
Augmentium Pharma Consulting, 283 Danforth Ave, Suite 448,
Toronto M4K 1N2, Canada
e-mail: george@augmentium.com
M. E. Lacouture
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
123
Breast Cancer Res Treat (2014) 147:631–638
DOI 10.1007/s10549-014-3126-0
particularly diarrhea and to a lesser extent, skin rash [3, 5].
Moderate to severe diarrhea and skin rash (C grade 2, as
defined by the National Cancer Institute Common Termi-
nology Criteria for Adverse Events (CTCAE)) were
reported in 20 and 5 % of patients’ in the pivotal trial,
respectively [3]. Grade 2 diarrhea is defined per CTCAE as
an increase of 4 to 6 stools per day over baseline. Grade 2
rash is defined as a scattered macular or papular eruption or
erythema with pruritus covering 10–30 % of body surface
area. Diarrhea and rash are of clinical concern because they
can lead to dose reductions, delays, reduce patient quality
of life, increase health care resource use, and can even be
life threatening [6–8].
Risk factors for diarrhea and rash have been identified,
but they have not been formally quantified, nor are they
specific to lapatinib [9, 10]. Therefore, occurrences of
DLTs such as diarrhea and rash during anticancer therapy
are largely believed to be unpredictable. As a result, the
traditional model (acting only after a patients develop the
toxicity) is still dominant because no reliable technology to
predict when these episodes will occur, and in whom is
available. The alternative, to intensely monitor and place
all patients on supportive care interventions for all cycles
of therapy is simply too expensive and time consuming for
most health care systems to sustain. What may be possible,
however, is a highly focused strategy based on mathe-
matical modeling to accurately identify patients at higher
than average risk, applied ‘‘just-in-time’’ to preempt epi-
sodes of DLTs such as diarrhea and rash. In other words, it
should be possible and economical to intervene preventa-
tively if we knew who is at higher risk and when (i.e., at
what cycle) the risk would become unacceptably high.
Such predictive models could then be made available as an
‘‘add-on’’ to existing computer-based chemotherapy
ordering systems or delivered through a hand-held
application.
To our knowledge, models for predicting the risk of
diarrhea and rash in breast cancer patients receiving small
molecule targeted therapies such as lapatinib have not been
previously described. Therefore, cycle-based repeated
measures prediction models for C grade 2 diarrhea and
rash were developed for patients receiving L-CAP. The
advantage of a repeated measures approach compared to a
model using baseline data only is that the former allows
risk to be continually reassessed following each additional
cycle of anticancer therapy. Repeated measures models
have been successfully developed for other toxicities in
cancer patients such as neutropenia and hand foot skin
reaction [11, 12]. In this study, the development of two
independent repeated measures (i.e., by cycle) prediction
models for grade C II diarrhea and rash and associated




Patient data for developing the repeated measures risk index
for C grade 2 diarrhea and rash for L-CAP were obtained from
the study initially reported by Geyer and colleagues[ 3]. This
was a large randomized trial comparing L-CAP to capecita-
bine alone in patients with advanced stage HER-2 positive
breast cancer [3, 4]. In that trial, a total of 399 patients who
were previously exposed to trastuzumab, anthracyclines, and
taxanes were randomized to receive capecitabine (2,000 mg/
m2 days 1 through 14 of a 21-day cycle) and oral lapatinib
1,250 mg daily (n = 198) or to capecitabine (2,500 mg/m2 -
days 1 through 14 of a 21-day cycle) alone [3, 4].
Baseline data collection included patient demographic
information, performance status, biochemistry, number and
site of metastases, prior therapies, and duration of prior
trastuzumab. The median dose per cycle of capecitabine and
lapatinib delivered in the experimental group was 22,500 and
26,250 mg, respectively [3, 4]. The mean duration of lapat-
inib was 135 days over a median of 6 cycles (range 1–36).
After a total of 1,617 cycles of L-CAP therapy, there were 93
and 19 C grade II diarrhea and rash events as defined by the
CTCAE. Therefore, two independent risk models were
developed for C grade II diarrhea and for C grade II rash
over a median of 6 cycles of L-CAP combination therapy.
Predictive factors for diarrhea and rash
and the development of risk algorithms
There have been reports that diarrhea in cancer patients
receiving chemotherapy is more prevalent in the elderly,
when treatment is started in the spring or summer months,
in earlier cycles of therapy and in those patients who
experienced grade I diarrhea in a prior cycle [9, 13, 14].
Similarly, risk factors for rash in patients receiving targeted
therapies include gender, age, and skin phototype [10, 15].
Certain polymorphisms have also been associated with
these toxicities [16]. Therefore, these potential risk factors
as well as others that were captured within the clinical trial
were considered in the development of each prediction
model and the associated scoring algorithms.
Patient demographic and clinical variables were
screened for possible inclusion into each risk model. To
identify the set of factors with the largest potential con-
tribution to diarrhea and skin rash risk, those with a p value
of 0.25 or less in a simple logistic regression with the
dependent variable of diarrhea and skin rash were retained
for further consideration. This is a recommended approach
for removing weak prognostic covariates so that a more
manageable set of variables can be submitted to multi-
variate techniques [17].
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Generalized estimating equations (GEE), which adjust
for patient clustering by cycle of therapy were used to
determine the final set of risk factors in each model [18,
19]. A GEE model was chosen since observations between
multiple cycles within the same patient would be expected
to violate the independence assumption of standard logistic
regression. The set of initially retained risk factors was
analyzed in the GEE model. The Likelihood ratio test was
then used in a backward elimination process (p \ 0.05 to
retain) to select the final set of risk factors for retention into
the model. The goodness of fit of the final models was then
assessed with the Hosmer–Lemeshow test. Model calibra-
tion was also evaluated by estimating a smooth calibration
line between the observed and predicted outcomes [20].
The calibration curve would equal one (optimal) if the
observed and predicted probabilities agree perfectly.
Nonparametric bootstrapping was then applied to test
the internal validity of the final prediction models [21, 22].
Resampled data (1,000 iterations) were used to generate
bootstrap estimates of the regression coefficients of the
multivariable model. The confidence intervals of the
regression coefficient estimates from the bootstrap sam-
pling were then compared with the values calculated by the
GEE regression analysis.
From the GEE regression model results, the contribution
of the individual risk factors to diarrhea and skin rash risk
was weighted with the final model coefficients. To simplify
calculations using these weights for the risk algorithms, the
coefficients were transformed by multiplying each by a
constant (derived by trial and error) and then rounding to
the nearest unit value. A summary diarrhea and skin rash
risk score was then assigned to each patient by simply
adding up transformed coefficient values (points) for each
risk factor they possessed.
The predictive accuracy of the final risk scoring indexes
for diarrhea and skin rash was then determined by mea-
suring the specificity, sensitivity, and area under the
Receiver Operating Characteristic (ROC) curve [23, 24].
Discrimination refers to the ability of a diagnostic test or a
predictive tool to accurately identify patients at low and
high risk for the event under investigation and is often
presented as the area under the ROC curve. A predictive
instrument with an ROC of C 0.70 is considered to have
good discrimination, and an area of 0.5 is equivalent to a
‘‘coin toss.’’ The statistical analyses were performed using
Stata, V11.0 (Stata Corp., College Station, Texas, USA).
Results
The clinical and disease characteristics of patients in the
model derivation sample are presented in Table 1. Patients
who received L-CAP had a median age of 53 years, and
over 95 % had a good performance status (as per trial
protocol). Prior to the first cycle of anticancer therapy,
hematological parameters were within normal limits, and
the median number of metastatic sites was two, with the
liver and bone being the most common. Approximately, 23
and 18 % of patients started therapy in the spring and
summer months, respectively. A total of 1,617 cycles of
L-CAP therapy were delivered over a 4–5-month period,
and there were 208 grade one diarrhea episodes. With
Table 1 Characteristics of patients and treatment received
Characteristic Derivation sample (n = 197)a























Total number of cycles
delivered
1,617
Median number of cycles
(range)
6 (1–36)












grade C 2 diarrhea
93 events at median of six, 21 day
cycles (5.8 % of cycles)
Development of
grade C 2 rash
19 events at median of six, 21 day
cycles (1.2 % of cycles)
ECOG Eastern Cooperative Oncology Group, Hb hemoglobin, WBC
white blood count
a Patients who actually received a starting dose of lapatinib
(1,250 mg daily) and capecitabine (2,000 mg/m2/day on days 1–14
every 3 weeks) within the trial
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respect to the primary endpoints, there were 93 and
19 C grade 2 diarrhea and skin rash episodes for an overall
event rate per cycle of 5.8 and 1.2 %, respectively
(Table 1).
Development of a risk prediction model for diarrhea
After the initial univariate screening of potential predictor
factors, the variables associated with C grade II diarrhea
retained for further analysis were age, presence of bone and
skin metastases at baseline, treatment being initiated in the
spring, serum creatinine, albumin and total bilirubin levels
in the prior cycle, and grade one diarrhea in the prior cycle.
The development of the diarrhea prediction model was
continued with multivariable GEE regression analysis and
the backward elimination process. The final variables
retained in the model that were significant predictive fac-
tors for diarrhea were advanced patient age, skin metasta-
ses at baseline, therapy being started in the spring, and
grade one diarrhea in the prior cycle (Table 2). A negative
association between risk and number of cycles was also
identified where the hazard for diarrhea was the highest in
earlier cycles and gradually declined by about 12 % in each
additional cycle (Table 2). The confidence intervals of
regression coefficient estimates from the bootstrap sam-
pling were comparable with the values calculated by the
GEE regression analysis, supporting the internal validity of
the model.
Development of a diarrhea scoring system
A risk scoring system was then developed from the point
estimates of the regression coefficients and the intercept
generated from the analysis. Each of the final regression
coefficients retained in the model provided a statistical
weight for that factor’s contribution to the overall risk of
diarrhea. The scoring system was then adjusted by adding a
constant across all scores to ensure that none were below
zero. The final product was a scoring system between 0 and
250 where higher scores were associated with an increased
risk for a diarrhea event (Table 3 and Fig. 1).
Table 2 Final predictive factors for diarrhea and rash derived from the dataset
Variablea Odds ratio (95 %CI)b Impact relative risk
Predictors for grade C 2 diarrhea
Patient age 1.03 (1.0–1.06) : by 3 % for each year
Each additional cycle 0.88 0.80–0.95) ; by 12 % per cycle
Skin metastases at baseline 0.29 (0.11–0.73) ; by 71 %
Grade I diarrhea in prior cycle 2.0 (0.98–4.3) : two fold
Therapy started in the spring 2.1 (1.2–3.6) : two fold
Predictors for grade C 2 rash
Planned dose of capecitabine/cycle (grams) 1.03 (0.99–1.08) : by 3 % with each gram
Brain metastases at baseline 6.0 (0.97–37.6) : 6 fold
Concomitant use of 5HT3 antiemetics 25.4 (11–59) : 25 fold
a These are the final variables that were retained following the application of the Likelihood ratio test (p \ 0.05 to retain) in a backwards
elimination process
b 95 %CI determined by nonparametric bootstrapping
Table 3 Risk scoring algorithm for C grade 2 diarrhea and skin rash
in patients receiving lapatinib and capecitabine
Predictive factor Start lapatinib/
capecitabine
Diarrhea: baseline score 100
Impact of predictor factors
Patient age Add patient’s age
Skin metastases at baseline Subtract 50
First cycle was started in April, May or
June
Add 25
Grade I diarrhea in the prior cycle Add 25
Current cycle number Multiply by 5, then
subtract
Total composite diarrhea risk scorea ?
Skin rash: baseline score 0
Impact of prediction factors Add 50
Brain metastases at baseline
Total planned capecitabine dose in
grams
Add total dose
Concomitant use of a 5HT3 antiemeticb Add 100
Total composite rash risk scorec ?
a The probability of developing C grade 2 diarrhea during that cycle
of lapatinib therapy can then be estimated from Fig. 1
b Ondansetron, granisetron, tropisetron, or palonesetron
c The probability of developing C grade 2 skin rash during that cycle
of lapatinib therapy can then be estimated from Fig. 2
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Factors that elevate the overall score are considered to
be positive risk factors for diarrhea. For instance, patient
age would be added to the baseline score of 100, so an
older patient would be at higher risk for diarrhea than a
younger patient (Table 3). In contrast, patients with skin
metastases at baseline are at a reduced risk for diarrhea, so
such patients would have 50 units subtracted from their
cumulative risk score. This risk scoring system can then be
applied to an individual patient prior to the start of L-CAP
and also prior to the next cycle in order to monitor the risk
of C grade II diarrhea throughout the entire course of
therapy. As an illustration, a 60-year-old HER-2 positive
patient (base score = 100) with bone only metastases who
started lapatinib and capecitabine in the spring would have
a risk score of 185 units prior to starting her first cycle.
This would correspond to a model estimated diarrhea risk
of approximately 24 % during the first cycle of therapy
(Figs. 1 and 3). However, as therapy is continued, the risk
of diarrhea would decline with each additional cycle
(Fig. 2). Therefore, the findings would suggest that the
most critical period of dose limiting diarrhea with L-CAP
is during the first few cycle of therapy.
All patients in the sample were then assigned a risk
score based on the algorithm (Table 3). The model devel-
opment was continued with an ROC analysis and a mea-
surement of the area under the ROC curve. The findings
suggested that the area under the ROC curve was good at
0.78 (95 %CI: 0.72–0.82), supporting the internal validity
of the scoring algorithm.
The final step in the development of the diarrhea pre-
diction tool was the identification of a high-risk score
threshold or ‘‘cutoff,’’ which optimizes sensitivity and
specificity. Four risk score categories were developed
(Table 4). The analysis identified a risk score threshold
of [ 125 as being the point where sensitivity and speci-
ficity are optimal, keeping in mind that tradeoffs between
these two measures need to be made (Table 4). Hence, a
risk score threshold of [ 125 would capture patients with a
diarrhea risk of at least 4.2 % prior to each cycle of L-CAP
therapy (Fig. 2).
Development of a risk prediction model and algorithm
for rash
A similar process was used to develop the risk prediction
algorithm for rash. However, with only 19 events, it must
be acknowledged that there was limited power to identify
statistically significant predictors of skin rash. Using a
backward elimination process with a preset alpha at 0.05,
the factors that were significantly associated with the
development of C grade II rash were the presence of brain
metastases at baseline, the planned dose of capecitabine in
grams for the given cycle, and the concomitant use of
5HT3 antiemetics (Table 2).
From the regression coefficients of these predictive
factors, a scoring algorithm between 0 and 150 was
developed where higher scores were associated with an
increased risk of skin rash. With the estimated risk score,
the probability of developing C grade 2 skin rash during
that cycle of lapatinib therapy can then be estimated from
Fig. 2. As with the diarrhea model, all patients in the
sample were then assigned a risk score based on the above
algorithm. The ROC curve analysis suggested an accept-
able AUC (0.67; 95 %CI: 0.54–0.81), but with somewhat
weaker predictive accuracy that the diarrhea scoring
algorithm.
The final step in the development of the skin rash pre-
diction tool was the identification of a high-risk score
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Fig. 1 Relationship between patient risk score and probability of
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Fig. 2 Relationship between patient risk score and probability of
developing C grade 2 skin rash
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risk score categories were developed (Table 4). The ana-
lysis identified a risk score threshold of [ 40 as being the
point where sensitivity and specificity are optimal. A risk
score threshold of [ 40 would capture patients with a skin
rash risk of at least 1.6 % risk prior to each cycle of L-CAP
therapy (Fig. 2).
Discussion
Diarrhea and rash are frequent AEs to agents targeting
HER1 and 2 [25]. Our study describes the development of
predictive models and scoring algorithms for grade C 2
(moderate to severe) diarrhea and skin rash in advanced
stage HER-2 positive breast cancer patients receiving la-
patinib and capecitabine. After an initial starting point of
31 and 25 potential predictor variables for diarrhea and
skin rash, the final independent risk models each contained
4–5 variables that were retained by statistical means. In the
case of diarrhea, the findings that advanced patient age,
therapy being started in the spring, a higher incidence in
earlier cycles, and grade I diarrhea in a prior cycle as risk
factors were not unexpected and consistent with earlier
reports [9, 13, 14]. However, a reduced risk of diarrhea in
patients with skin metastases has not to our knowledge
been previously reported and warrants further
investigation.
In the case of skin rash, risk was increased by elevating
the dose of capecitabine, in patients with brain metastases
and in cases where concomitant 5HT3 antiemetics were
used. Since risk factors for skin rash in patients receiving
the L-CAP combination have never been evaluated, so the
identification of the above predictors should be considered
exploratory, requiring confirmation in a planned external
validation study.
There has been considerable research in the area of
prediction modeling, but the majority of work has been on
neutropenia and its associated complications [11, 20]. To
our knowledge, these are the first predictive tools that have
been developed for moderate to severe diarrhea and skin in
patients receiving targeted therapy with lapatinib. Diarrhea
and skin rash are both associated with substantial morbidity
Table 4 Detailed analysis of risk scoring system for C grade 2 diarrhea and skin rash
Score cut point Observed riska (%) Model estimated riska (%) Sensitivity (%) Specificity (%) Likelihood ratioc
Diarrhea
B75 0.5 B0.8 100 0 1.0
[75 to B125 2.4 0.8–4.2 99 14 1.2
[125 to B175a 8.8 4.2–18.8 82 56 1.9
[175 25 [18.8 17 97 5.5
Skin rash
B20 0.7 \1 100 0 1.0
[20 to B30 1.0 1–1.2 79 37 1.3
[30 to B40 1.9 1.2–1.6 32 92 3.9
[40c 6 [1.6 26 95 5.5
a Patients with a risk score of [125 to B175 had a diarrhea prevalence of approximately 8.8 % during that cycle of lapatinib therapy as observed
in the patient sample. Patients with scores of [ 125 would have a model estimated diarrhea risk of [ 4.2 %. Therefore in our analysis, we
considered a diarrhea risk score of [ 125 to be ‘‘high risk’’
b Patients with a risk score of [ 40 had a rash prevalence of approximately 6 % during that cycle of lapatinib therapy. Therefore in our analysis,
we considered a skin rash risk score of [ 40 to be ‘‘high risk’’
c The ratio of the probability of a positive test result, in the case of diarrhea, a risk score of 125 units or more among patients who actually
developed C grade 2 diarrhea to the probability of a positive test result among patients who did not develop such an event. Therefore, patients
















Fig. 3 Risk of diarrhea over the first eight cycle of therapy for a
60 year old patient, with bone only metastases who started lapatinib
and capecitabine in the spring
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affecting patient quality of life and high cost to the health
care system [7, 8, 26, 27]. Therefore, the ability to preempt
these episodes with the use of validated mathematical
algorithms will improve patient quality of life, reduce pain,
and suffering and avoid unnecessary health care
expenditures.
Important advantages of our repeated measures models
are that they are straightforward to apply and able to dis-
criminate between high and low risk patients. The risk
threshold for medical decision-making can also be shifted
up or down, depending on a patient’s risk tolerance. Such
scoring systems can also be incorporated into chemother-
apy ordering systems or even delivered through a hand-
held device. Another advantage of a cycle-based prediction
model over one that uses prechemotherapy baseline vari-
ables only is that the latter cannot predict at what cycle the
risk becomes elevated. With only a baseline risk assess-
ment, the clinician would be unable to forewarn the patient
and target the appropriate use of preventative therapies
when risk becomes unacceptably high.
Despite these attributes, there are a number of limita-
tions in the models that need to be acknowledged. The
current risk prediction algorithms for diarrhea and skin
should be seen as work in progress because they have yet to
undergo external and temporal validation on a new sample
of patients [20, 28, 29]. Validation studies to address these
limitations are currently underway. The models considered
data on only readily measurable variables that were cap-
tured in the clinical trial. For instance, data on patient skin
phototype was not available. Therefore, not all of the
variability was accounted for in our analysis. In the sample
of 197 patients, there were only 19 (1.2 % of cycles)
moderate to severe skin rash events, which challenged the
model development because the ratio between the numbers
of events per variable retained in any model should be at
least 10–1 [30]. The model development sample was
patients who were enrolled into a clinical trial. It has been
well documented in the literature that trial patients are
predominantly Caucasian, younger and with a better
overall performance status than non-trial patients [31]. As a
result, it must be acknowledged that such drawbacks could
compromise the generalizability of our models to patients
outside of the clinical trial setting.
Despite these limitations, we provide an important
starting point for optimizing the use of this active drug
combination. The mathematical algorithms were easy to
apply and able to identify patients at high-risk prior to each
cycle of lapatinib and capecitabine. The external validation
and eventual clinical application of these prediction tools
will be an important source of patient-specific risk infor-
mation for the practicing oncologist and can enhance
patient care by utilizing preventative strategies in a pro-
active manner
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